Showing 1321-1330 of 1554 results for "".
- Silicon Valley Eye Doctor Named Optometrist of the Year By American Optometric Associationhttps://modernod.com/news/silicon-valley-eye-doctor-named-optometrist-of-the-year-by-american-optometric-association/2480071/The California Optometric Association (COA) announced that David M. Redman, OD, has been named the “Optometrist of the Year” for 2017 by the American Optometric Association (AOA). Dr. Redman is a practicing optometrist and partner in Precision Eyecare Centers in San Jose and Mountain View. Dr. Re
- Vantage EyeCare Expands in Philadelphia Area With the Addition of Three Eyecare Practiceshttps://modernod.com/news/vantage-eyecare-expands-in-philadelphia-area-with-the-addition-of-three-eyecare-practices/2479718/Vantage EyeCare LLC has added three eye care companies to its operations, according to a report in VisionMonday. The three are: Century E
- Biotech Healthcare Unveils Optiflex XTENSE Comfort Plus EDOF IOL in Europehttps://modernod.com/news/biotech-healthcare-unveils-optiflex-xtense-comfort-plus-edof-iol/2484159/Biotech Healthcare has launched the Optiflex XTENSE Comfort Plus: Full Visual Range EDOF IOL. The Optiflex XTENSE Comfort Plus, which was launched at the European Society of Cataract & Refractive Surgeons (E
- New Funding for Orbis International Will Increase Global Access to Eye Care Through Technologyhttps://modernod.com/news/new-funding-for-orbis-international-will-increase-global-access-to-eye-care-through-technology/2477136/This Giving Tuesday, Orbis International announced the launch of its Silicon Valley Orbis Innovation Fund, which seeks to raise $8 million in donations to harness the next generation of technology that will revolutionize the future of e
- Noveome Biotherapeutics Announces Publication of Further Preclinical Results Supporting the Neuroprotective Properties of ST266 in Retinal Ganglion Cellshttps://modernod.com/news/noveome-biotherapeutics-announces-publication-of-further-preclinical-results-supporting-the-neuroprotective-properties-of-st266-in-retinal-ganglion-cells/2476572/Noveome Biotherapeutics announced the publication of preclinical results for ST266, its proprietary, cell-free platform biologic, published in the Journal of Neuro-Ophthalmology. These new results further support the neuroprotective properties of intranasally delivered ST266 in mice with e
- SECO International Names Dr. R. Max Raynor as 2021 Presidenthttps://modernod.com/news/seco-international-names-dr-r-max-raynor-as-2021-president/2477497/SECO International has named R. Max Raynor, OD, as the next president. His term began on March 7, 2020, and will last through February 28, 2021. Dr. Raynor officially accepted the honor during the House of Delegates meeting held on Saturday, March 7 at SECO 20/20. “Dr. Raynor has dedicated
- AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into Phase 1/2 Clinical Trialhttps://modernod.com/news/aavantgarde-receives-fda-clearance-to-progress-stargardt-disease-asset-aavb-039-into-phase-12-clinical-trial/2482885/AAVantgarde Bio announced that the FDA has cleared its investigational new drug (IND) application for AAVB-039, the company’s gene therapy program for Stargardt disease. AAVantgarde is now initiating CELESTE, a first-in-human phase 1/2 clinical trial in the United States to e
- Bausch + Lomb Launches Blink Nourish and Blink Boost Lubricating Eye Drops in the UShttps://modernod.com/news/bausch-lomb-launches-blink-nourish-and-blink-boost-lubricating-eye-drops-in-the-us/2482834/Bausch + Lomb announced the US launch of Blink Nourish and Blink Boost lubricating eye drops. According to B+L, both products are preservative-free, contact-lens friendly and uniquely formulated to provide hydration and comfort for dry e
- Adverum Initiates ARTEMIS Phase 3 Study to Evaluate Ixo-vec for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-initiates-artemis-phase-3-study-to-evaluate-ixo-vec-for-wet-amd/2482686/Adverum Biotechnologies announced the initiation of ARTEMIS phase 3 study to evaluate Ixo-vec gene therapy (ixoberogene soroparvovec) as a one-time intravitreal (IVT) injection for neovascular (wet) age-related macular degeneration (AMD). Wet AMD is a leading cause of blindness in the e
- Bausch + Lomb Launches Opal Digital Marketplace in the UShttps://modernod.com/news/bausch-lomb-launches-opal-digital-marketplace-in-the-us/2482465/Bausch + Lomb announced the US launch of Opal, a new digital e-commerce marketplace designed to enhance efficiency for eye care practices while improving the patient experience. The platform provides a streamlined and user-friendly ordering process for Bausch + Lomb’s contact lens